Jarno Satopää

Jarno Satopää

Auto-generated profile, based on publicly available information

Jarno Satopää

University of Helsinki, Finland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Stroke
Verified
Journal Article
Closed access
PDF file
AMAtte Meretoja
Atte Meretoja
DSDaniel Strbian
Daniel Strbian
JPJukka Putaala
Jukka Putaala
SCSami Curtze
Sami Curtze
EHElena Haapaniemi
Elena Haapaniemi
TTTurgut Tatlisumak
Turgut Tatlisumak
Background and Purpose—: The purpose of this study was to provide a simple and practical clinical classification for the etiology of intracerebral hemorrhage (ICH). Methods—: We performed a retrospective chart review of consecutive patients with ICH treated at the Helsinki University Central Hospital, January 2005 to March 2010 (n=1013). We classified ICH etiology by predefined criteria as structural vascular lesions (S), medication (M), amyloid angiopathy (A), systemic disease (S), hypertension (H), or undetermined (U). Clinical and radiological features and mortality by SMASH-U (Structural lesion, Medication, Amyloid angiopathy, Systemic/other disease, Hypertension, Undetermined) etiology were analyzed. Results—: Structural lesions, namely cavernomas and arteriovenous malformations, caused 5% of the ICH, anticoagulation 14%, and systemic disease 5% (23 liver cirrhosis, 8 thrombocytopenia, and 17 various rare conditions). Amyloid angiopathy (20%) and hypertensive angiopathy (35%) were common, but etiology remained undetermined in 21%. Interrater agreement in classifying cases was high (κ, 0.89; 95% CI, 0.82–0.96). Patients with structural lesions had the smallest hemorrhages (median volume, 2.8 mL) and best prognosis (3-month mortality 4%), whereas anticoagulation-related ICHs were largest (13.4 mL) and most often fatal (54%). Overall, median ICH survival was 5½ years, varying strongly by etiology ( P <0.001). After adjustment for baseline characteristics, patients with structural lesions had the lowest 3-month mortality rates (OR, 0.06; 95% CI, 0.01–0.37) and those with anticoagulation (OR, 1.9; 1.0–3.6) or other systemic cause (OR, 4.0; 1.6–10.1) the highest. Conclusions—: In our patients, performing the SMASH-U classification was feasible and interrater agreement excellent. A plausible etiology was determined in most patients but remained elusive in one in 5. In this series, SMASH-U based etiology was strongly associated with survival.

1 July 2014 in Stroke
Verified
Journal Article
Closed access
PDF file
EHElena Haapaniemi
Elena Haapaniemi
DSDaniel Strbian
Daniel Strbian
CRCostanza Rossi
Costanza Rossi
JPJukka Putaala
Jukka Putaala
TSTuulia Sipi
Tuulia Sipi
AMAtte Meretoja
Atte Meretoja
Background and Purpose—: Seizures are a common complication of intracerebral hemorrhage (ICH). We developed a novel tool to quantify this risk in individual patients. Methods—: Retrospective analysis of the observational Helsinki ICH Study (n=993; median follow-up, 2.7 years) and the Lille Prognosis of InTra-Cerebral Hemorrhage (n=325; 2.2 years) cohorts of consecutive ICH patients admitted between 2004 and 2010. Helsinki ICH Study patients’ province-wide electronic records were evaluated for early seizures occurring within 7 days of ICH and among 7-day survivors (n=764) for late seizures (LSs) occurring >7 days from ICH. A Cox regression model estimating risk of LSs was used to derive a prognostic score, validated in the Prognosis of InTra-Cerebral Hemorrhage cohort. Results—: Of the Helsinki ICH Study patients, 109 (11.0%) had early seizures within 7 days of ICH. Among the 7-day survivors, 70 (9.2%) patients developed LSs. The cumulative risk of LSs was 7.1%, 10.0%, 10.2%, 11.0%, and 11.8% at 1 to 5 years after ICH, respectively. We created the CAVE score (0–4 points) to estimate the risk of LSs, with 1 point for each of cortical involvement, age 10 mL, and early seizures within 7 days of ICH. The risk of LSs was 0.6%, 3.6%, 9.8%, 34.8%, and 46.2% for CAVE scores 0 to 4, respectively. The c-statistic was 0.81 (0.76–0.86) and 0.69 (0.59–0.78) in the validation cohort. Conclusions—: One in 10 patients will develop seizures after ICH. The risk of this adverse outcome can be estimated by a simple score based on baseline variables.

21 August 2014 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
RKR.‐J. Koivunen
R.‐J. Koivunen
JSJ. Satopää
J. Satopää
AMA. Meretoja
A. Meretoja
DSD. Strbian
D. Strbian
EHE. Haapaniemi
E. Haapaniemi
JPJ. Putaala
J. Putaala

1 November 2014 in World Neurosurgery
Verified
Journal Article
Closed access
HLHanna Lehto
Hanna Lehto
AHAli Harati
Ali Harati
MNMika Niemelä
Mika Niemelä
RDReza Dashti
Reza Dashti
ALAki Laakso
Aki Laakso
JHJuha Hernesniemi
Juha Hernesniemi

1 August 2017 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
JSJarno Satopää
Jarno Satopää
SMSatu Mustanoja
Satu Mustanoja
AMAtte Meretoja
Atte Meretoja
JPJukka Putaala
Jukka Putaala
MKMarkku Kaste
Markku Kaste
DSDaniel Strbian
Daniel Strbian

8 April 2015 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
RKR.‐J. Koivunen
R.‐J. Koivunen
TTT. Tatlisumak
T. Tatlisumak
JSJ. Satopää
J. Satopää
MNM. Niemelä
M. Niemelä
JPJ. Putaala
J. Putaala